GlassScriptPhysician profile
Ulises M Caraballo
NPI 1962464461
$8,727.99
in general payments reported to CMS, 2019-2025
39 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $890 · 2021: $2,288 · 2022: $1,642 · 2023: $1,169 · 2024: $769 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,240.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,178.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $998.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $630.54 | 2019-2025 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $625.20 | 2019-2024 | Spravato |
| Amgen INC. | $540.43 | 2019-2024 | Otezla, Repatha |
| Dexcom, INC. | $536.54 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbott Laboratories | $454.07 | 2021-2023 | Freestyle Libre 3 |
| Pfizer INC. | $390.04 | 2019-2025 | |
| Abbvie INC. | $380.36 | 2019-2024 | Qulipta, Ubrelvy |
| Medtronic, INC. | $284.49 | 2021-2022 | |
| Glaxosmithkline, LLC. | $281.86 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.58 | 2019-2025 | Jardiance, Synjardy |
| Sunovion Pharmaceuticals INC. | $188.90 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $141.56 | 2022-2023 | Quviviq |
| Cvrx, INC. | $132.15 | 2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulises Caraballo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.